Pfizer and BioNTech's coronavirus vaccine is safe and effective in children ages 5 to 11, albeit at a lower dose than adults receive, the companies said in a press release announcing results from a pediatric trial.
Why it matters: The trial results are a much-needed source of hope for families with elementary school-aged children, who currently aren't eligible for a vaccine.
What they found: Children given two doses of the vaccine 21 days apart had comparable antibody responses to people ages 16 to 25 who participated in an earlier trial.
- The younger children received doses that were a third the size of those administered to people 12 and older.
- Vaccine side effects were also comparable to trial participants who were 16- to 25-years-old.
- The data has not yet been submitted for peer review.
What's next: The companies said they "expect to include the data in a near-term submission" to the FDA for emergency authorization.
- "These trial results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency," Pfizer Chairman and CEO Albert Bourla said in a statement.
